Company news
Liminal BioSciences Inc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange
July 22, 2020
Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases
July 17, 2020
Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy
July 2, 2020
Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors
June 30, 2020
Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020
June 30, 2020
Liminal BioSciences to Present at Raymond James Human Health Innovation Conference
June 11, 2020
Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting Of Shareholders (AGM)
June 9, 2020
Liminal BioSciences to present at Jefferies Virtual Healthcare Conference
May 28, 2020
Liminal Biosciences Reports Q1 2020 Results
May 13, 2020
Liminal BioSciences comments on Coronavirus (COVID-19)
March 22, 2020
Liminal Biosciences Reports Fourth Quarter and 2019 Year End Results
March 20, 2020
Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast
March 20, 2020
Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia
February 12, 2020
Liminal BioSciences announces upcoming investor presentation at BIO CEO & Investor Conference
February 6, 2020
Liminal BioSciences Outlines Corporate Priorities for 2020
January 13, 2020
Liminal BioSciences Comments on Unusual Market Activity
December 23, 2019
AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019
November 28, 2019
Liminal BioSciences to Present at Piper Jaffray Healthcare Conference
November 27, 2019
Liminal BioSciences announces closing of divestiture of bioseparations division to KKR
November 25, 2019
Liminal Presents New Preclinical Data on PBI-4050 and its Effect on Angio-Proliferative Pulmonary Arterial Hypertension
November 18, 2019
Liminal BioSciences to Present at the Jefferies 2019 London Healthcare Conference
November 18, 2019
Liminal Biosciences announces effectiveness of Registration Statement on Form F-10 and filing of Prospectus Supplement
November 18, 2019
Liminal BioSciences to Present at Stifel Healthcare Conference
November 15, 2019
Liminal BioSciences to Commence Trading Common Shares on NASDAQ
November 15, 2019
/C O R R E C T I O N from Source -- Liminal BioSciences Inc./
November 14, 2019
Liminal Biosciences Announces Key Appointment to its Leadership Team
November 13, 2019
Liminal BioSciences Presents New Preclinical Data on PBI-4050 and NASH Candidate PBI-4547
November 12, 2019
Liminal BioSciences to Report Q3 2019 Results and Hold Conference Call
November 11, 2019
Liminal BioSciences Reports its 2019 Third Quarter Financial Results and Business Highlights
November 11, 2019
Liminal Biosciences Presents New Preclinical Data at ASN Kidney Week 2019
November 11, 2019
Liminal BioSciences to Divest Bioseparations Division to KKR
November 4, 2019
Liminal BioSciences announces upcoming presentations new data on pulmonary arterial hypertension at the 2019 AHA meeting
October 29, 2019
Liminal BioSciences announces upcoming presentations at The Liver Meeting 2019
October 25, 2019
Liminal BioSciences Announces Upcoming Presentations at ASN Kidney Week 2019
October 24, 2019
Liminal BioSciences to Present At H.C. Wainwright & Co. 3rd Annual NASH Investor Conference
October 18, 2019
Prometic Shareholders Approve Name Change to Liminal BioSciences Inc.
October 3, 2019
Prometic Life Sciences Announces Intention to Change Name to Liminal BioSciences Inc.
September 3, 2019
Calls
Decks
The 5 newest of 6 decks. Every deck is listed under its year.
- Investor Presentation (June 2023)
Investor deck · 33 slides · Jun 2, 2023
- Shareholder Meeting (May 2023)
Shareholder meeting · 5 slides · May 2, 2023
- Investor Presentation (January 2023)
Investor deck · 21 slides · Jan 6, 2023
- Shareholder Meeting (December 2022)
Shareholder meeting · 4 slides · Dec 15, 2022
- Investor Presentation (September 2022)
Investor deck · 19 slides · Sep 13, 2022